Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 69.21 Billion KRW | 18.06% |
| 2022 | 57.98 Billion KRW | 3.27% |
| 2021 | 56.14 Billion KRW | -4.45% |
| 2020 | 58.76 Billion KRW | 23.93% |
| 2019 | 47.41 Billion KRW | 4.16% |
| 2018 | 45.52 Billion KRW | -6.92% |
| 2017 | 48.9 Billion KRW | -1.81% |
| 2016 | 49.81 Billion KRW | -1.71% |
| 2015 | 50.67 Billion KRW | 4.3% |
| 2014 | 48.58 Billion KRW | 3.99% |
| 2013 | 46.72 Billion KRW | -20.96% |
| 2012 | 59.11 Billion KRW | 41.51% |
| 2011 | 41.77 Billion KRW | -26.35% |
| 2010 | 56.71 Billion KRW | 10.39% |
| 2009 | 51.37 Billion KRW | -4.34% |
| 2008 | 53.71 Billion KRW | 19.26% |
| 2007 | 45.03 Billion KRW | 2.08% |
| 2006 | 44.12 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.4 Billion KRW | -6.48% |
| 2024 Q2 | 18.77 Billion KRW | 8.4% |
| 2023 Q1 | 14.77 Billion KRW | -3.96% |
| 2023 Q4 | 18.6 Billion KRW | 198.42% |
| 2023 FY | 68.45 Billion KRW | 18.06% |
| 2023 Q3 | -18.9 Billion KRW | -212.65% |
| 2023 Q2 | 16.78 Billion KRW | 13.61% |
| 2022 FY | 57.98 Billion KRW | 3.27% |
| 2022 Q1 | 14.48 Billion KRW | -16.88% |
| 2022 Q4 | 15.38 Billion KRW | 10.59% |
| 2022 Q2 | 14.2 Billion KRW | -1.88% |
| 2022 Q3 | 13.9 Billion KRW | -2.11% |
| 2021 Q1 | 11.33 Billion KRW | -25.69% |
| 2021 Q2 | 13.5 Billion KRW | 19.19% |
| 2021 Q3 | 13.87 Billion KRW | 2.74% |
| 2021 Q4 | 17.42 Billion KRW | 25.54% |
| 2021 FY | 56.14 Billion KRW | -4.45% |
| 2020 Q3 | 14.43 Billion KRW | -17.17% |
| 2020 Q2 | 17.42 Billion KRW | 50.34% |
| 2020 FY | 58.76 Billion KRW | 23.93% |
| 2020 Q1 | 11.58 Billion KRW | -12.74% |
| 2020 Q4 | 15.25 Billion KRW | 5.69% |
| 2019 Q3 | 11.13 Billion KRW | -9.48% |
| 2019 FY | 47.41 Billion KRW | 4.16% |
| 2019 Q1 | 10.69 Billion KRW | -13.36% |
| 2019 Q2 | 12.3 Billion KRW | 14.98% |
| 2019 Q4 | 13.28 Billion KRW | 19.28% |
| 2018 FY | 45.52 Billion KRW | -6.92% |
| 2018 Q4 | 12.34 Billion KRW | 14.52% |
| 2018 Q3 | 10.78 Billion KRW | -4.46% |
| 2018 Q2 | 11.28 Billion KRW | 1.62% |
| 2018 Q1 | 11.1 Billion KRW | -5.9% |
| 2017 Q4 | 11.8 Billion KRW | -4.12% |
| 2017 Q1 | 12.21 Billion KRW | 8.65% |
| 2017 FY | 48.9 Billion KRW | -1.81% |
| 2017 Q2 | 12.58 Billion KRW | 3.06% |
| 2017 Q3 | 12.3 Billion KRW | -2.21% |
| 2016 Q4 | 11.24 Billion KRW | -6.28% |
| 2016 Q1 | 11.95 Billion KRW | -2.36% |
| 2016 Q2 | 14.61 Billion KRW | 22.23% |
| 2016 Q3 | 11.99 Billion KRW | -17.95% |
| 2016 FY | 49.81 Billion KRW | -1.71% |
| 2015 Q3 | 11.86 Billion KRW | -10.91% |
| 2015 Q4 | 12.24 Billion KRW | 3.21% |
| 2015 FY | 50.67 Billion KRW | 4.3% |
| 2015 Q1 | 13.24 Billion KRW | -2.46% |
| 2015 Q2 | 13.32 Billion KRW | 0.57% |
| 2014 Q1 | 11.58 Billion KRW | 3.03% |
| 2014 Q4 | 13.57 Billion KRW | 11.0% |
| 2014 Q3 | 12.23 Billion KRW | 9.3% |
| 2014 Q2 | 11.19 Billion KRW | -3.39% |
| 2014 FY | 48.58 Billion KRW | 3.99% |
| 2013 Q1 | 12.26 Billion KRW | 10.19% |
| 2013 FY | 46.72 Billion KRW | -20.96% |
| 2013 Q3 | 12.27 Billion KRW | 12.12% |
| 2013 Q4 | 11.24 Billion KRW | -8.39% |
| 2013 Q2 | 10.94 Billion KRW | -10.74% |
| 2012 Q4 | 11.12 Billion KRW | -10.58% |
| 2012 FY | 59.11 Billion KRW | 41.51% |
| 2012 Q2 | 15.15 Billion KRW | -24.82% |
| 2012 Q3 | 12.44 Billion KRW | -17.86% |
| 2012 Q1 | 20.15 Billion KRW | 0.0% |
| 2011 Q3 | 14.01 Billion KRW | 26.58% |
| 2011 Q1 | 13.41 Billion KRW | -8.97% |
| 2011 Q2 | 11.07 Billion KRW | -17.44% |
| 2011 FY | 41.77 Billion KRW | -26.35% |
| 2010 Q4 | 14.73 Billion KRW | 3.13% |
| 2010 FY | 56.71 Billion KRW | 10.39% |
| 2010 Q1 | 12.62 Billion KRW | 5.16% |
| 2010 Q2 | 14.28 Billion KRW | 13.13% |
| 2010 Q3 | 14.28 Billion KRW | 0.02% |
| 2009 Q2 | 13.99 Billion KRW | 3.46% |
| 2009 Q3 | 12.77 Billion KRW | -8.73% |
| 2009 Q4 | 12 Billion KRW | -5.99% |
| 2009 FY | 51.37 Billion KRW | -4.34% |
| 2009 Q1 | 13.52 Billion KRW | 0.71% |
| 2008 Q3 | 13.02 Billion KRW | -5.59% |
| 2008 FY | 53.71 Billion KRW | 19.26% |
| 2008 Q2 | 13.79 Billion KRW | 28.23% |
| 2008 Q4 | 13.43 Billion KRW | 3.12% |
| 2008 Q1 | 10.75 Billion KRW | -5.38% |
| 2007 Q3 | 11.41 Billion KRW | -0.73% |
| 2007 FY | 45.03 Billion KRW | 2.08% |
| 2007 Q2 | 11.49 Billion KRW | 0.0% |
| 2007 Q4 | 11.37 Billion KRW | -0.37% |
| 2006 FY | 44.12 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -46.472% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 76.773% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 75.142% |
| HANDOK Inc. | 153.76 Billion KRW | 54.988% |
| Yuhan Corporation | 489.94 Billion KRW | 85.873% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 77.452% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -65.624% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 88.672% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 3.848% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.256% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -72.804% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 26.016% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 39.67% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -46.472% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -62.964% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 7.776% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -18.023% |
| JW Holdings Corporation | 301.25 Billion KRW | 77.025% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 73.477% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 83.063% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.03% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 45.787% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -1.321% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -5.266% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 60.433% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -46.472% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 72.217% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 87.65% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.03% |
| Yuhan Corporation | 489.94 Billion KRW | 85.873% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 64.261% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 0.367% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -23.525% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.03% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 45.239% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 41.451% |
| CKD Bio Corp. | 25.19 Billion KRW | -174.703% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 68.823% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 58.081% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -4.21% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 45.787% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 80.265% |
| Boryung Corporation | 285.16 Billion KRW | 75.728% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 20.937% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.256% |
| JW Lifescience Corporation | 20.26 Billion KRW | -241.6% |